Telaprevir’s Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations
This article was originally published in Pharmaceutical Approvals Monthly
Groups with historically poor responses to standard hepatitis C therapy made good progress when the direct-acting antiviral telaprevir was added to their regimen, Vertex Pharmaceuticals Inc. reported at the American Association for the Study of Liver Diseases Meeting in Boston.
You may also be interested in...
About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.
Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).
Vertex released solid top-line data from a second Phase III study supporting a response-guided regimen that could halve the current 48-week standard course for many patients.